[NEWS RELEASE Skystar Bio-Pharmaceutical Reports Second Quarter 2011 Results $9.1 Million Top Line; $0.21 Diluted EPS; Expanded Direct Distribution and Sales Channels XI’AN, CHINA – August 23, 2011 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2011 Highlights · Revenue increases 10% YoY to $9.1 million · Veterinary vaccines totaled $0.4million, up 1.2% YoY · Veterinary]
[NEWS RELEASE Skystar Bio-Pharmaceutical Reports Second Quarter 2011 Results $9.1 Million Top Line; $0.21 Diluted EPS; Expanded Direct Distribution and Sales Channels XI’AN, CHINA – August 23, 2011 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2011 Highlights · Revenue increases 10% YoY to $9.1 million · Veterinary vaccines totaled $0.4million, up 1.2% YoY · Veterinary]
[FORM 8-K CURRENT REPORT Date of report (Date of earliest event reported): August 23, 2011 (August 19, 2011) EVER-GLORY INTERNATIONAL GROUP, INC. Florida 000-28806 65-0420146 (State or other jurisdiction of incorporation or organization) (Commission File No.) (IRS Employee Identification No.) Ever-Glory Commercial Center, 509 Chengxin Road, Jiangning Development Zone, Nanjing, Jiangsu Province, Peoples Republic of China (8625) 5209-6875 (Issuer Telephone]
[FORM 8-K CURRENT REPORT Date of report (Date of earliest event reported): August 23, 2011 (August 19, 2011) EVER-GLORY INTERNATIONAL GROUP, INC. Florida 000-28806 65-0420146 (State or other jurisdiction of incorporation or organization) (Commission File No.) (IRS Employee Identification No.) Ever-Glory Commercial Center, 509 Chengxin Road, Jiangning Development Zone, Nanjing, Jiangsu Province, Peoples Republic of China (8625) 5209-6875 (Issuer Telephone]
[CUSIP No. G210821050 Page 2 of 8 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) o (b) 3 SEC USE ONLY 4]
[CUSIP No. P8696W104 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) WC 5]
[CUSIP No. P8696W104 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) WC 5]
[ReneSola Announces US$100 Million Share Repurchase Program JIASHAN, China, August 22, 2011 – Under the program, the Company may, from time to time, for a limited Mr. Xianshou Li, ReneSola’s chief executive officer and director, commented, “At present, we believe our shares are undervalued. Despite relatively weak capital markets and a challenging solar market, we are confident in the long-term] [RENESOLA LTD No. 8 Baoqun Road, YaoZhuang Jiashan, Zhejiang 314117 People’s Republic of China x ¨ Form 20-F ¨ x Yes N/A 82- RENESOLA LTD Xianshou Li Xianshou Li Chief Executive Officer]
[ReneSola Announces US$100 Million Share Repurchase Program JIASHAN, China, August 22, 2011 – Under the program, the Company may, from time to time, for a limited Mr. Xianshou Li, ReneSola’s chief executive officer and director, commented, “At present, we believe our shares are undervalued. Despite relatively weak capital markets and a challenging solar market, we are confident in the long-term] [RENESOLA LTD No. 8 Baoqun Road, YaoZhuang Jiashan, Zhejiang 314117 People’s Republic of China x ¨ Form 20-F ¨ x Yes N/A 82- RENESOLA LTD Xianshou Li Xianshou Li Chief Executive Officer]
